Establishing analytical workflows for complex biopharmaceutical molecules can help predict their risk of degradation.
raimund14/Stock.adobe.com
Biopharmaceuticals are complex molecules with a variety of functional groups that are susceptible to instability through different degradation pathways. Protein degradation may arise as a result of exposure to different environmental changes and stresses throughout the product lifecycle. Molecular variants arising during manufacture and/or storage may not have properties comparable to those of the desired product with respect to their activity, efficacy, and most importantly, safety. Therefore, it is crucial to set up analytical workflows to understand the intrinsic biochemical and physical stability of these molecules and predict the risk of degradants formation. This paper describes the application of biophysical stability parameters that measure solution-mediated interactions and key structural characteristics of model proteins that will enable a fast assessment of conformational and colloidal stability of biopharmaceuticals.
Click
herefor a PDF of this article.
Submitted: Feb. 24, 2021
Accepted: April 9, 2021
Joana S. Cristóvão*, PhD, jscristovao@hovione.com, is an analytical scientist, and Salomé Neto was a Master’s student, both with Hovione Farmaciência S.A., R&D, Analytical Development.
*To whom all correspondence should be addressed.
BioPharm International
Vol. 34, No. 9
September 2021
Pages: 34–40
When referring to this article, please cite it as J.S. Cristóvão and S. Neto, “Conformational and Colloidal Stability Studies to Predict the Best Biopharmaceutical Formulation,” BioPharm International 34 (9) 34–40 (2021).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.